Finance

Lists
C17:FRA
Corvus Pharmaceuticals Inc
€9.14
-1.15%
(-0.11) 1D
Nov 19, 10:00:00 PM GMT+1  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for C17...
Open
€8.95
High
€9.14
Low
€8.95
Mkt. cap
844.37M
Avg. vol.
4.00
Volume
0.00
52-wk high
€21.70
52-wk low
€5.49
No. of employees
37
Open
€8.95
High
€9.14
Low
€8.95
Mkt. cap
844.37M
Avg. vol.
4.00
Volume
0.00
52-wk high
€21.70
52-wk low
€5.49
No. of employees
37
News stories
From web sources and news partners
About Corvus Pharmaceuticals Inc
CEO-
Employees37
Founded2014
HeadquartersBurlingame, California, United States
SectorHealth Care
IndustryBiotechnology
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
9.94M
11.18M
15.96M
17.78M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.28M
3.70M
3.33M
3.58M
Operating expense
12.22M
14.88M
19.30M
21.36M
Total operating expenses
12.22M
14.88M
19.30M
21.36M
Operating income
-12.22M
-14.88M
-19.30M
-21.36M
Other non operating income
-
-
-
-
EBT including unusual items
-12.32M
-13.69M
-17.96M
-20.34M
EBT excluding unusual items
-12.32M
-13.69M
-17.96M
-20.34M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-12.32M
-13.69M
-17.96M
-20.34M
Net profit margin
-
-
-
-
Earnings per share
-0.15
-0.15
-0.19
-0.22
Interest and investment income
603.00K
1.78M
2.05M
1.91M
Interest expense
-
-
-
-
Net interest expenses
603.00K
1.78M
2.05M
1.91M
Depreciation and amortization charges
-
-
-
-
EBITDA
-12.19M
-14.85M
-19.26M
-21.27M
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps